Morgan Keegan Reiterates Outperform and PT of $115 on C.R. Bard

Morgan Keegan reiterated its Outperform rating on C.R. Bard BCR. At the same time, the rating agency left its price target on the company's stock unchanged at $115. On Thursday, BCR added 0.6% to its value to finish the day at $112.71. In today's pre-market trading, its shares lost 6.08% of their value to stand around $105.86.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: ReiterationAnalyst RatingsHealth CareHealth Care EquipmentMorgan Keegan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!